Attached files
| file | filename |
|---|---|
| EX-99.1 - INTERPACE BIOSCIENCES, INC. | ex99-1.htm |
| 8-K - INTERPACE BIOSCIENCES, INC. | form8-k.htm |
Sent via Electronic Delivery to: jstover@interpacedx.com
September 18, 2017
Mr. Jack E. Stover
Chief Executive Officer
Interpace Diagnostics Group, Inc.
Morris Corporate Center 1, Building A
300 Interpace Parkway, Parsippany, NJ 07054
| Re: | Interpace Diagnostics Group, Inc. (the “Company”) |
| Nasdaq Symbol: IDXG |
Dear Mr. Stover:
On October 6, 2016, Staff notified the Company that it did not comply with the audit committee requirements for continued listing on The Nasdaq Capital Market set forth in Listing Rule 5605(c)(2) (the “Rule”). Based on the information regarding the appointment of Dr. Felice Schnoll-Sussman to the Company’s Board of Directors and audit committee, as detailed in your Form 8-K dated September 13, 2017, Staff has determined that the Company complies with the Rule and this matter is now closed.
If you have any questions, please contact Shawn Abdool, Listing Analyst, at +1 301 978 8030.
Sincerely,
Randy Genau
Director
Nasdaq Listing Qualifications